세계의 WGA(Whole Genome Amplification) 시장(2024-2031년)

Global Whole Genome Amplification Market Size, Share & Trends Analysis Report by Product Type (Instruments, Kits and Reagents, and Services), by Application (Drug Discovery and Development, Disease Diagnosis, Agriculture, Veterinary Research, Forensics, and Others), and by End-User (Pharma and Biotech Companies, Contract Research Organizations, Academic Institutes, and Others) Forecast Period (2024-2031)

Whole genome amplification market is anticipated to grow at a CAGR of 7.3% during the forecast period (2024-2031). Whole genome amplification is the process of amplifying the entire genome from nanogram quantities of DNA to microgram quantities of amplified products. It has been used to amp up material from a single DNA cell and is an important tool for the preservation of small samples of DNA products. Numerous techniques, such as primer extension preamplification, multiple displacement amplification, and degenerate oligonucleotide PCR, have been developed for whole genome amplification.

Market Dynamics

Growing demand for research and development in genetic testing

One of the main factors driving market expansion is the increasing requirement for research and development in the fields of genetic testing, genomics, biological research, and molecular diagnostics. In January 2024, Sano Genetics, a software company accelerating precision medicine research raised $11.4 million in new funding, led by Plural with participation from existing investors including MMC Ventures, Episode 1 and Seedcamp. The growing funding for genetic testing startups is further aiding the research related to genetic testing.

Rising DNA multiplication technologies

The market is driven primarily by the rapidly growing array of improved DNA multiplication technologies. Due to the advances in technology related to loop-mediated amplification, a great deal of research has been done on advanced technologies and their alternatives, including Nucleic Acid Sequence Based Amplification (NASBA), Rolling Circle Amplification (RCA), and Loop-Mediated Isothermal Amplification (LAMP). These methods are becoming more popular due to their benefits, which include facile multiplication from a single cell, fast amplification kinetics, and no need for costly heat cycles. These elements are anticipated to increase consumer demand for the goods sold in this market and, as a result, boost organic revenue growth.

Market Segmentation

• Based on product type, the market is segmented into instruments, kits and reagents, and services.
• Based on application, the market is segmented into drug discovery and development, disease diagnosis, agriculture, veterinary research, forensics, and others including precision medicine.
• Based on end-user, the market is segmented into pharma and biotech companies, contract research organizations, academic institutes, and others including hospitals & clinics.

Drug Discovery Holds Major Share Based on Application

The growing research on diseases including cancer and genetic disorders, increasing technological developments, and new drug discovery techniques implemented are key contributors to the high share of this market segment. For instance, in July 2021, Eli Lilly and Verge Genomics entered a partnership to research and create new drugs for the treatment of amyotrophic lateral sclerosis (ALS). With this new partnership, Verge developed an all-in-human, artificial-intelligence (AI)-driven drug discovery and development platform to develop treatments for serious genetic diseases. This new platform is being used to advance them into clinical trials and markets.

Regional Outlook

The global whole genome amplification market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Asia-Pacific countries to invest in healthcare sector

• The Asia-Pacific market is growing as it has favorable government initiatives to develop better healthcare infrastructure.
• The market expansion in nations, such as China and India, has boosted the easy availability of skilled labor and increased research efforts in the field of genomics and molecular diagnostics.

North America Holds Major Market Share

The presence of robust biotechnology R&D infrastructure in the region along with the significant presence of numerous genetic research initiatives are key contributors to the high share of the regional market. Furthermore, a sizable portion of businesses involved in the production and marketing of gene amplification solutions that are kits, reagents, and instruments have their headquarters in the US. This element also played a role in the region's high revenue generation. Apart from this, the growing geriatric population and the high healthcare expenditure of the regional population are further aiding the demand for the regional market.

The major companies serving the global whole genome amplification market include GE Healthcare, Illumina, Inc., Agilent Technologies, Inc., Merck KGaA, and Thermo Fisher Scientific Inc. among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers and acquisitions among others to stay competitive in the market. For instance, in April 2021, Hologic acquired Mobidiag, an innovator in near-patient, acute care diagnostic testing, for approximately $795 million. With this acquisition, the company intends to expand its footprint in the diagnostic testing market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Industry Trends
  • 2.2.2. Market Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Agilent Technologies Inc.
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. GE Healthcare
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Illumina Inc.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Thermo Fisher Scientific Inc.
  • 3.5.1. Overview
  • 3.5.2. Financial Analysis
  • 3.5.3. SWOT Analysis
  • 3.5.4. Recent Developments
• 3.6. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Whole Genome Amplification Market by Product Type
  • 4.1.1. Instruments
  • 4.1.2. Kits & Reagents
  • 4.1.3. Services
• 4.2. Global Whole Genome Amplification Market by Application
  • 4.2.1. Drug Discovery and Development
  • 4.2.2. Disease Diagnosis
  • 4.2.3. Agriculture
  • 4.2.4. Veterinary Research
  • 4.2.5. Forensics
  • 4.2.6. Others (Precision Medicine)
• 4.3. Global Whole Genome Amplification Market by End-User
  • 4.3.1. Pharma and Biotech Companies
  • 4.3.2. Contract Research Organizations
  • 4.3.3. Academic Institutes
  • 4.3.4. Others (Hospitals & Clinics)

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World
  • 5.4.1. Latin America
  • 5.4.2. Middle East & Africa

6. Company Profiles

• 6.1. 23&Me Inc.
• 6.2. Bio-Rad Laboratories, Inc.
• 6.3. Danaher Corp.
• 6.4. Eurofins Scientific SE
• 6.5. F. Hoffmann-La Roche Ltd.
• 6.6. Luminex Corp.
• 6.7. Merck KGaA
• 6.8. Myriad Genetics Inc.
• 6.9. Oxford Nanopore Technologies
• 6.10. Pacific Biosciences of California Inc.
• 6.11. PerkinElmer Inc.
• 6.12. Promega Corp.
• 6.13. Qiagen NV
• 6.14. Quest Diagnostics
• 6.15. Silicon Biosystems
• 6.16. Takara Bio Inc.
• 6.17. Vazyme Biotech Co. Ltd.